Compare · FRLN vs NBIX
FRLN vs NBIX
Side-by-side comparison of Freeline Therapeutics Holdings plc (FRLN) and Neurocrine Biosciences Inc. (NBIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRLN and NBIX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- NBIX carries a market cap of $16.48B.
- NBIX has hit the wire 11 times in the past 4 weeks while FRLN has been quiet.
- NBIX has more recent analyst coverage (25 ratings vs 6 for FRLN).
- Company
- Freeline Therapeutics Holdings plc
- Neurocrine Biosciences Inc.
- Price
- -
- -
- Market cap
- -
- $16.48B
- 1M return
- -
- +13.81%
- 1Y return
- -
- +16.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1996
- News (4w)
- 0
- 11
- Recent ratings
- 6
- 25
Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Latest FRLN
- Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- SEC Form 15-12G filed by Freeline Therapeutics Holdings plc
- SEC Form EFFECT filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form POS AM filed by Freeline Therapeutics Holdings plc
- SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)
- SEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)
Latest NBIX
- Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Chief Medical Officer Roberts Eiry was granted 8,314 stock options and was granted 1,506 restricted stock units (SEC Form 4)
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
- Director Morrow George J exercised 15,000 shares at a strike of $53.64 and sold $2,335,982 worth of shares (15,000 units at $155.73) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Gano Kyle converted options into 614 shares and covered exercise/tax liability with 332 shares, increasing direct ownership by 0.18% to 155,010 units (SEC Form 4) to satisfy withholding obligation
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- SEC Form 10-Q filed by Neurocrine Biosciences Inc.
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia